Limits...
The promise and challenge of personalized medicine: aging populations, complex diseases, and unmet medical need.

Henney AM - Croat. Med. J. (2012)

Bottom Line: It is also being seen as one approach that may have a beneficial impact on reducing health care budgets.But what are the challenges that need to be addressed in its implementation in the clinic?This article poses some provocative questions and suggests some things that need to be considered.

View Article: PubMed Central - PubMed

Affiliation: Obsidian Biomedical Consulting Ltd., Macclesfield, UK. adriano.henney@virtual-liver.de

ABSTRACT
The concept of personalized medicine is not new. It is being discussed with increasing interest in the medical, scientific, and general media because of the availability of advanced scientific and computational technologies, and the promise of the potential to improve the targeting and delivery of novel medicines. It is also being seen as one approach that may have a beneficial impact on reducing health care budgets. But what are the challenges that need to be addressed in its implementation in the clinic? This article poses some provocative questions and suggests some things that need to be considered.

Show MeSH
Number of new chemical or biological entities (1990-2009). Source: SCRIP-EFPIA calculations (according to nationality of mother company), reproduced with permission from The Pharmaceutical Industry in Figures, EFPIA, 2010 edition (2). Europe – dark gray; USA – white; Japan – horizontal lines; others – light gray.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3368289&req=5

Figure 3: Number of new chemical or biological entities (1990-2009). Source: SCRIP-EFPIA calculations (according to nationality of mother company), reproduced with permission from The Pharmaceutical Industry in Figures, EFPIA, 2010 edition (2). Europe – dark gray; USA – white; Japan – horizontal lines; others – light gray.

Mentions: These diseases are areas of major focus for novel therapies, and have been for some time, but the success of bringing innovative medicines to market over the last couple of decades has been poor, despite the wealth of technical advancements experienced in medical sciences. Pharmaceutical industry figures (2) show that the full cost of bringing a new medicine to market has risen sharply since 1975, from some US $140 million to an estimated US $1300 million by 2006 (Figure 2). In contrast, the success of delivery of new medicines to market has declined significantly over the same period, despite our increased “knowledge” of disease mechanisms and pathways (Figure 3).


The promise and challenge of personalized medicine: aging populations, complex diseases, and unmet medical need.

Henney AM - Croat. Med. J. (2012)

Number of new chemical or biological entities (1990-2009). Source: SCRIP-EFPIA calculations (according to nationality of mother company), reproduced with permission from The Pharmaceutical Industry in Figures, EFPIA, 2010 edition (2). Europe – dark gray; USA – white; Japan – horizontal lines; others – light gray.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3368289&req=5

Figure 3: Number of new chemical or biological entities (1990-2009). Source: SCRIP-EFPIA calculations (according to nationality of mother company), reproduced with permission from The Pharmaceutical Industry in Figures, EFPIA, 2010 edition (2). Europe – dark gray; USA – white; Japan – horizontal lines; others – light gray.
Mentions: These diseases are areas of major focus for novel therapies, and have been for some time, but the success of bringing innovative medicines to market over the last couple of decades has been poor, despite the wealth of technical advancements experienced in medical sciences. Pharmaceutical industry figures (2) show that the full cost of bringing a new medicine to market has risen sharply since 1975, from some US $140 million to an estimated US $1300 million by 2006 (Figure 2). In contrast, the success of delivery of new medicines to market has declined significantly over the same period, despite our increased “knowledge” of disease mechanisms and pathways (Figure 3).

Bottom Line: It is also being seen as one approach that may have a beneficial impact on reducing health care budgets.But what are the challenges that need to be addressed in its implementation in the clinic?This article poses some provocative questions and suggests some things that need to be considered.

View Article: PubMed Central - PubMed

Affiliation: Obsidian Biomedical Consulting Ltd., Macclesfield, UK. adriano.henney@virtual-liver.de

ABSTRACT
The concept of personalized medicine is not new. It is being discussed with increasing interest in the medical, scientific, and general media because of the availability of advanced scientific and computational technologies, and the promise of the potential to improve the targeting and delivery of novel medicines. It is also being seen as one approach that may have a beneficial impact on reducing health care budgets. But what are the challenges that need to be addressed in its implementation in the clinic? This article poses some provocative questions and suggests some things that need to be considered.

Show MeSH